AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2013

Oct 15, 2013

33651_dirs_2013-10-15_38c18247-2d03-4747-92f0-a7964df297c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-10-11

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-10-11	Common Stock	A	2630	—	Acquired	17974	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	130376	Indirect

Footnotes

F1: The shares acquired were issued for the account of the reporting person at a value of $2.06 per share in payment of contingent value rights held by the reporting person.